Luo, Y., Assassi, S., Mayes, M. D., Frech, T. M., Steen, V. D., Richardson, C., … Bernstein, E. J. (2025). Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States. Ann Am Thorac Soc, 22(8), 1265–1269. https://doi.org/10.1513/AnnalsATS.202410-1045RL

Luo, Yiming, Shervin Assassi, Maureen D. Mayes, Tracy M. Frech, Virginia D. Steen, Carrie Richardson, Lorinda Chung, et al. “Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.” Ann Am Thorac Soc 22, no. 8 (August 2025): 1265–69. https://doi.org/10.1513/AnnalsATS.202410-1045RL.

Luo Y, Assassi S, Mayes MD, Frech TM, Steen VD, Richardson C, et al. Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States. Ann Am Thorac Soc. 2025 Aug;22(8):1265–9.

Luo, Yiming, et al. “Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.” Ann Am Thorac Soc, vol. 22, no. 8, Aug. 2025, pp. 1265–69. Pubmed, doi:10.1513/AnnalsATS.202410-1045RL.

Luo Y, Assassi S, Mayes MD, Frech TM, Steen VD, Richardson C, Chung L, Sandorfi N, VanBuren JM, Harding M, Alvey JS, Skaug B, McMahan ZH, Lakin KS, Zahn C, Bracken SJ, Lebiedz-Odrobina DJ, Molitor JA, Evnin LB, Moore DF, Shah A, Castelino FV, Volkmann ER, Hant FN, Makol A, Shah AA, Hummers LK, Gordon JK, Khanna D, Bernstein EJ. Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States. Ann Am Thorac Soc. 2025 Aug;22(8):1265–1269.